Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00912964 · ClinicalTrials.gov registry record · Phase 3
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase 3 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,030
- Enrollment target
NCT00912964 is a Phase 3 study that has completed, run by Astellas Pharma. The registered enrollment target is 2,030 participants.
The verdict
NCT00912964, a Phase 3 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,030 participants
- Enrollment target
Study Summary
The study is intended to test efficacy, safety and tolerability of two doses of once daily (qd) Mirabegron against placebo to treat patients with symptoms of overactive bladder.
Interventions
- DRUG Placebo
- DRUG Mirabegron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,030 participants |
| Start Date | 2009-04-28 |
| Est. Completion | 2010-04-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00912964
The ClinicalTrials.gov registry entry for NCT00912964 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,030 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00912964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00912964 about?
NCT00912964 is a clinical study titled "A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder". The study is intended to test efficacy, safety and tolerability of two doses of once daily (qd) Mirabegron against placebo to treat patients with symptoms of overactive bladder.
What is the current status of trial NCT00912964?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,030 participants. The study started on 2009-04-28. Estimated completion is 2010-04-27.
What interventions are being tested in trial NCT00912964?
The interventions under investigation include: Placebo (DRUG), Mirabegron (DRUG).
Who is sponsoring clinical trial NCT00912964?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.